Login to Your Account

Kite's white knight smites lymphoma in trial; CMO calls data 'astonishing'

By Randy Osborne
Staff Writer

Tuesday, August 26, 2014

Given a lift by phase I/IIa data with KTE-C19, its anti-CD19 chimeric antigen receptor (CAR) T-cell therapy for aggressive non-Hodgkin's lymphoma, Kite Pharma Inc. plans a pivotal study early next year in diffuse large B-cell lymphoma (DLBCL).

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription